Accuray Inc represents values of innovation, precision, and patient-centric care in the field of radiation oncology. With a corporate philosophy focused on improving the lives of cancer patients, Accuray Inc offers cutting-edge solutions like the CyberKnife and Radixact systems. These advanced technologies provide non-invasive and highly accurate treatment options, enabling personalized cancer care and improved quality of life. Accuray Inc aims to empower healthcare professionals with state-of-the-art tools, fostering collaboration and optimal treatment outcomes. As a global leader in radiation therapy, Accuray Inc continues to revolutionize cancer treatment, making a positive impact on patients worldwide.

Accuray Inc is primarily present in several countries and regions across the globe. The company has a strong presence in North America, with operations in the United States and Canada. Additionally, Accuray Inc has expanded its reach to Europe, including countries such as Germany, France, Italy, and the United Kingdom. The company is also present in the Asia-Pacific region, with a significant presence in Japan, China, India, and Australia. Accuray Inc's global presence allows it to cater to a wide range of markets and provide its innovative medical solutions to healthcare professionals worldwide.

Accuray Inc has achieved several significant milestones in its history. One notable achievement is the development and introduction of the CyberKnife System, a robotic radiosurgery system that revolutionized cancer treatment. The company also attained regulatory clearance for its innovative TomoTherapy System, which combines precise radiation therapy with integrated CT imaging. Accuray Inc has expanded its global reach, establishing a presence in over 100 countries worldwide. Moreover, the company has consistently demonstrated a commitment to innovation, investing in research and development to enhance its advanced treatment solutions. These achievements highlight Accuray Inc's dedication to improving cancer care and solidify its position as a leader in the field.

Accuray Inc. is a renowned medical technology company specializing in the development and sale of innovative radiation therapy solutions. Founded in 1990, Accuray is based in Sunnyvale, California. The company's flagship product, the CyberKnife System, is a non-invasive robotic radiosurgery system utilized for treating cancerous and non-cancerous tumors. With a blend of advanced robotics and real-time tumor tracking, Accuray's CyberKnife System enables precise delivery of radiation therapy, minimizing damage to surrounding healthy tissues. Over the years, Accuray has consistently introduced cutting-edge advancements in the field of radiosurgery, revolutionizing the way cancer is treated globally. Accuray's commitment to improving patient outcomes has made it a trusted name in the healthcare industry.

The main competitors of Accuray Inc in the market include Varian Medical Systems, Elekta AB, and ViewRay Inc.

Accuray Inc is primarily active in the medical technology industry.

The business model of Accuray Inc, a leading medical technology company, revolves around providing innovative and precise radiation therapy solutions for the treatment of multiple types of cancer. With their flagship product, the CyberKnife System, Accuray offers non-invasive treatment options that deliver targeted radiation directly to tumors while minimizing damage to surrounding healthy tissues. This state-of-the-art technology enables personalized treatment plans tailored to each patient's unique needs, increasing treatment effectiveness and minimizing side effects. By combining advanced hardware and software solutions, Accuray Inc aims to enhance patient outcomes and improve the quality of life for individuals battling cancer.

Accuray의 P/E 비율은 -170.07입니다.

Accuray의 P/S 비율은 0.28입니다.

AlleAktien 품질 점수는 현재 Accuray에 대해 계산할 수 없습니다.

예상되는 Accuray 매출은 463.83 백만 USD입니다.

예상되는 Accuray 이익은 -751,780.8 USD입니다.

Accuray Inc is a global manufacturer of medical devices for the radiation therapy treatment of cancer. The company's main products are the CyberKnife and TomoTherapy systems. The company also offers a range of services and support facilities for its devices. In addition, Accuray Inc also provides software solutions for medical imaging and workflow management. The CyberKnife systems by Accuray target tumor and non-tumor areas for precise treatment. This system uses robotic precision and image-guided technology to deliver radiation to the exact location where the tumor is located. This method spares healthy cells and allows for complete recovery. The CyberKnife system is used in diverse treatment areas including brain tumors, liver tumors, spine cancer, and prostate cancer. The TomoTherapy system is a computer-assisted procedure that integrates imaging and radiation planning in one system. The TomoTherapy systems combine continuous, rotating radiation source with precise imaging technology for accuracy and precision in radiation therapy. This system is used for various types of cancer including head and neck cancer, breast cancer, lung cancer, and prostate cancer. Accuray also offers software solutions for medical imaging and workflow management. The iDMS software by Accuray enables healthcare facilities to automatically manage and monitor their session bookings, orders for radiation therapy, and approved quantity. The uMI software allows for easy and effective imaging and radiation planning for the CyberKnife and TomoTherapy systems. The company also operates a clinical services division which provides a variety of management and support services including training, installation, technical support, and system maintenance. Accuray's commitment to customer satisfaction from this division is a crucial part of its business model as these services ensure the long-term safety and efficacy of the systems. Accuray sells its products to leading hospitals and medical centers in the USA, Europe, Asia, and other parts of the world. The company targets customers with a high need for precise radiation therapy, including oncologists, radiation therapists, and other medical professionals. Accuray's business model creates value by providing innovative and effective cancer treatment devices and software solutions. The company also has a high appreciation in the clinical division, which ensures the long-term health of customers. The demand for precise radiation therapy will continue to grow as the cancer rate in the population increases. This makes Accuray's business model sustainable and will continue to expand in the future.

Accuray은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Accuray의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Accuray의 ISIN은 US0043971052입니다.

Accuray의 WKN은 A0MKWM입니다.

Accuray의 티커는 ARAY입니다.

지난 12개월 동안 Accuray은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Accuray은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Accuray의 현재 배당 수익률은 입니다.

Accuray은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Accuray은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Accuray은 '건강' 섹터에 속합니다.

Accuray의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2024년에 Accuray는 0 USD를 배당금으로 지급했습니다.

Accuray의 배당금은 USD에 지급됩니다.